
---
title: '在外国_翻车_的疫苗，国内还有戏吗？'
categories: 
 - 新媒体
 - 果壳网
 - 科学人
headimg: 'https://2-im.guokr.com/csjtvk19N0Pkr4dkxI9iQBbR7unt95jeL0OArI8yOXFkAAAAZAAAAFBO.png'
author: 果壳网
comments: false
date: Fri, 23 Apr 2021 02:16:27 GMT
thumbnail: 'https://2-im.guokr.com/csjtvk19N0Pkr4dkxI9iQBbR7unt95jeL0OArI8yOXFkAAAAZAAAAFBO.png'
---

<div>   
<section style="font-size: 15px;color: rgb(62, 62, 62);letter-spacing: 1.5px;line-height: 2.25;padding-right: 8px;padding-left: 8px;box-sizing: border-box;"><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;">5月将近，全球新冠疫苗接种工作仍在争分夺秒地推进，见诸媒体的副反应案例亦日渐增多。值得注意的是，这些副反应，多数源于腺病毒疫苗。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-align: right;white-space: normal;box-sizing: border-box;"><span style="font-size: 14px;box-sizing: border-box;">陈颖 | 作者</span></p><p style="text-align: right;white-space: normal;box-sizing: border-box;"><span style="font-size: 14px;box-sizing: border-box;">李拓丨编辑</span></p><p style="text-align: right;white-space: normal;box-sizing: border-box;"><span style="font-size: 14px;box-sizing: border-box;">放大灯团队 | 策划</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">世卫组织信息显示，到4月中旬，各国已经批准的疫苗中，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">基于腺病毒载体的新冠疫苗获批最多（达到4款）</span>，超过其它类型的疫苗<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[1]</span>。它们的研发者分别是英国牛津-阿斯利康（含印度血清研究所）、强生、俄罗斯加马列亚国家研究中心+俄罗斯直接投资基金（RDIF）、中国军科院+康希诺生物股份公司（以下简称康希诺）。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">由于副反应案例较多，阿斯利康疫苗曾在今年3月一度被挪威、冰岛、奥地利、丹麦等十国暂停使用。4月14日，丹麦国家卫生局与药品管理局干脆宣布，不再为国民接种牛津-阿斯利康疫苗，成为全球首个停用阿斯利康疫苗的国家<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[2]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在美国，6名女性因接种强生（Johnson & Johnson）新冠疫苗出现罕见严重血栓病例（年龄分布为18岁至48岁）。当地时间4月13日，美国FDA、CDC共同宣布，建议暂停接种强生腺病毒载体新冠疫苗<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[3]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">虽然现在并不能断定腺病毒新冠疫苗彻底“翻车”，但中国的腺病毒新冠疫苗公司，将面临两个大问题。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;width: 12.5%;height: auto;box-sizing: border-box;"><img data-ratio="1" data-src="https://2-im.guokr.com/csjtvk19N0Pkr4dkxI9iQBbR7unt95jeL0OArI8yOXFkAAAAZAAAAFBO.png" data-type="png" data-w="100" style="vertical-align: middle;width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/csjtvk19N0Pkr4dkxI9iQBbR7unt95jeL0OArI8yOXFkAAAAZAAAAFBO.png" referrerpolicy="no-referrer"></section></section><section style="max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;justify-content: center;align-items: center;flex-direction: column;max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;box-sizing: border-box;"><section style="display: flex;padding-top: 3px;padding-bottom: 3px;flex-direction: column;justify-content: center;border-bottom: 2px dashed rgb(219, 175, 105);max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="text-align: unset;background-color: rgb(255, 206, 0);padding-left: 15px;padding-right: 15px;padding-top: 1px;max-width: 100%;font-size: 16px;color: rgb(17, 17, 17);box-sizing: border-box;"><p style="min-width: 1px;font-weight: bold;box-sizing: border-box;"><strong style="box-sizing: border-box;">安全问题：百万分之一的血栓概率</strong></p></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">1953 年，科研人员从从腺样组织分离出来“人腺病毒”（human adenovirus，HAdV）。目前，该病毒已经发现共 7 种（A ~ G）、60 多个血清型。全球范围内仅美国对 HAdV 疫苗进行过系统性的研究<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[4]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">腺病毒可以作为载体，进行各种疫苗的研发。</span>新冠疫苗只是其中一种。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在新冠疫苗之前，被批准面向大众使用的腺病毒载体疫苗，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">只有两款埃博拉疫苗。</span>（可移步至<span style="color: rgb(219, 175, 105);box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=Mzg2MTUyODU2NA==&mid=2247515382&idx=1&sn=49befbcd5112ec4464dd73f0571c1027&chksm=ce17346df960bd7b05936074a0389925ec965ad651013640a13d0b7be9c0d06ae9ad3e497875&scene=21#wechat_redirect" textvalue="《腺病毒载体安全吗？| 117三人行》" data-itemshowtype="0" tab="innerlink" data-linktype="2">《腺病毒载体安全吗？| 117三人行》</a></span>，了解腺病毒疫苗的历史）</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">2017年10月，中国的腺病毒埃博拉疫苗（Ad5-EBOV）获批。这款疫苗由中国军科院与康希诺联合研发。但它仅用于应急使用及国家储备<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[5]</span>，后续未大规模量产<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[6]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">2020年7月，强生的腺病毒埃博拉疫苗Zabdeno获得欧盟委员会（EC）批准。这款疫苗以人26型腺病毒（Ad26)为载体，与另一只疫苗Mvabea组成了一套双剂接种方案。到2020年3月，Zabdeno在全球的接种量<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">才刚刚超过21.5万剂</span><span style="color: rgb(219, 175, 105);box-sizing: border-box;">[7]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">使用腺病毒进行疫苗研究开发的，还有结核病疫苗等。以结核病疫苗为例，各家都还在临床试验阶段，当前均未获批和量产。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 14px;color: rgb(219, 175, 105);padding-right: 16px;padding-left: 16px;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;">Clinicaltrials.gov的最新数据显示，牛津大学正在招募Ⅱ期临床试验志愿者；俄罗斯生物生物安全问题研究所已完成Ⅰ期临床试验；麦克马斯特大学则有两项临床，一项在招募Ⅰ期入组志愿者，另一项Ⅰ期已结束。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.4407407" data-src="https://1-im.guokr.com/tauhQc5RrP9RNR7YUfWW4D9yqgE6oyBX7TLDwIJBHpk4BAAA3AEAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;" src="https://1-im.guokr.com/tauhQc5RrP9RNR7YUfWW4D9yqgE6oyBX7TLDwIJBHpk4BAAA3AEAAFBO.png?imageView2/1/w/555/h/244" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;color: rgb(219, 175, 105);box-sizing: border-box;">全球新型结核病疫苗进展：使用腺病毒载体的有麦克马斯特+康希诺、俄罗斯生物安全问题研究所和牛津大学[8]。</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">也就是说，在新冠疫情之前，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">全球从未有接种百万、千万级别规模腺病毒疫苗的先例。</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">一位疫苗专家在接受《第一财经》采访时表示，腺病毒疫苗导致血栓非常罕见。<span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">只有在</span>阿斯利康或者强生这样大规模的接种中，才会发生<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[9]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">阿斯利康和强生新冠疫苗的接种规模有多大？</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">数据显示，发现6名血栓病例时，强生疫苗在美国共接种约680万剂<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[3]</span>。4月16日，全球疫苗安全咨询委员会称，英国国民接种阿斯利康疫苗后，出现血栓的概率约每100万成年人中有4例（疫苗在英国已接种超2000万剂）。而在欧盟，这一风险约为每10万例中有1例<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[10]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">综合来看，腺病毒疫苗导致血栓的概率在<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">十万分之一到二十五万分之一。</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">全球共有4款腺病毒疫苗获批上市。中国民众能打上的，其实只有天津康希诺生物的重组腺病毒疫苗Ad5-nCov（商品名“克威莎”）。这款疫苗于2021年2月25日获NMPA附条件批准上市。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.462963" data-src="https://3-im.guokr.com/qlBXlASsSrOl3145kVC3gnUxAT0013WZgEA2a2fD2KA4BAAA9AEAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;" src="https://3-im.guokr.com/qlBXlASsSrOl3145kVC3gnUxAT0013WZgEA2a2fD2KA4BAAA9AEAAFBO.png?imageView2/1/w/555/h/256" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">由于同为腺病毒技术路线，在美国监管方建议强生疫苗暂停接种的消息传出后，波动立刻传导了过来——4月14日，康希诺A、H股股价双双大跌。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">康希诺急忙救场，它在当天盘中发布公告称，其重组新冠病毒疫苗使用的载体是5型腺病毒，与强生、阿斯利康的<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">病毒载体均有所不同</span>——阿斯利康使用的是黑猩猩腺病毒载体，强生使用的是人26型腺病毒载体（Ad26)。</p><p style="white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;">且截至公告日，接种其疫苗<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">约百万人</span>中未收到与血栓相关的严重不良事件的报告<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[11]</span>。截至收盘，康希诺A股股价跌6.29%，H股股价跌7.54%。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">强生、阿斯利康的疫苗是在接种数百万乃至上千万剂后，才出现了血栓个例。康希诺的疫苗是否会导致血栓，或许要等待更大规模的数据。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">4月21日，联防联控机制科研攻关组疫苗研发专班专家组成员邵一鸣表示，目前还没有观察到康希诺腺病毒载体新冠疫苗导致血栓的报告。但是药监部门要求，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">在监控当中特别关注使用腺病毒载体疫苗的血栓问题。</span>“我们国家有非常健全的不良反应监测系统，这个可以让百姓放心，一旦发现任何问题，我们会采取措施。”<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[12]</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">一位腺病毒疫苗行业人士对放大灯团队（ID：guokr233）表示，尽管强生与阿斯利康出现了血栓问题，但接种腺病毒疫苗利大于弊，算是目前的行业共识。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">对国内腺病毒新冠疫苗公司来说，除了悬而未决的安全争议，产能问题可能更棘手。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;width: 12.5%;height: auto;box-sizing: border-box;"><img data-ratio="1" data-src="https://2-im.guokr.com/4YFCG9dwB9Z3ay8lwqUWItK8OQj9enI3RkloOIl-2XxkAAAAZAAAAFBO.png" data-type="png" data-w="100" style="vertical-align: middle;width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/4YFCG9dwB9Z3ay8lwqUWItK8OQj9enI3RkloOIl-2XxkAAAAZAAAAFBO.png" referrerpolicy="no-referrer"></section></section><section style="max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;justify-content: center;align-items: center;flex-direction: column;max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;box-sizing: border-box;"><section style="display: flex;padding-top: 3px;padding-bottom: 3px;flex-direction: column;justify-content: center;border-bottom: 2px dashed rgb(219, 175, 105);max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="text-align: unset;background-color: rgb(255, 206, 0);padding-left: 15px;padding-right: 15px;padding-top: 1px;max-width: 100%;font-size: 16px;color: rgb(17, 17, 17);box-sizing: border-box;"><p style="min-width: 1px;font-weight: bold;box-sizing: border-box;"><strong style="box-sizing: border-box;">腺病毒疫苗，不是想造就能造</strong></p></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">事实上，国内生产重组腺病毒疫苗的厂商，不只康希诺一家。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">公开资料显示，目前，我国从事腺病毒新冠疫苗生产的企业，至少有6家。其中，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">康希诺是自主研发和生产，</span>并已接种了约100万剂。其余几家则是引进外企疫苗或代工，且都还未启动疫苗生产。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-align: center;"><img class="rich_pages js_insertlocalimg" data-ratio="0.56171875" data-s="300,640" data-src="https://1-im.guokr.com/Qe-S-txjc297dgZxn8Ja4GFVfEOJp--lyQkIn4D2JME4BAAAXwIAAFBO.png" data-type="png" data-w="1280" style src="https://1-im.guokr.com/Qe-S-txjc297dgZxn8Ja4GFVfEOJp--lyQkIn4D2JME4BAAAXwIAAFBO.png?imageView2/1/w/555/h/311" referrerpolicy="no-referrer"></p><p style="white-space: normal;box-sizing: border-box;"><br></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;">国内某腺病毒疫苗生产厂商的高层向放大灯团队介绍，在我国生物制药行业，腺病毒疫苗对生产工艺的要求比较高，算是一个新领域。<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">此前能量产腺病毒疫苗的厂商，国内目前几乎没有。</span>目前说是要进行腺病毒疫苗生产的企业们，其实也都还在建设产能。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">这位业内人士还补充到，虽然康希诺的腺病毒疫苗已获批准，但施打的人却很少，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">就是在产能上遇到了问题。</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">但康希诺管理层对产能的预计却十分乐观。在2020年业绩交流会上，康希诺管理层表示，目前公司有3个新冠疫苗生产基地——已投产的天津工厂，7月份投产的上海工厂，两地工厂分别有2亿~3亿剂年产能。此外，外部委托生产的产能约有1亿剂<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[13]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">以此计算，今年康希诺的产能可达到5亿至7亿剂。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">克威莎的上市，让连年亏损的康希诺有了第一款上市产品。财报显示，公司2020年营收为2489.04万，较上年增长2260多万。归母净利则亏损3.97亿，较上一年扩大2.40亿<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[14]</span>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">毫无疑问，克威莎的市场表现，将直接影响康希诺在商业化元年的表现。</p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.8453704" data-src="https://2-im.guokr.com/c7oK4oofNWeUI9WcByWjJyE1NEeklFiQGtnBjGl14iE4BAAAkQMAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;width: 376px;height: 318px;" src="https://2-im.guokr.com/c7oK4oofNWeUI9WcByWjJyE1NEeklFiQGtnBjGl14iE4BAAAkQMAAFBO.png?imageView2/1/w/555/h/469" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;color: rgb(219, 175, 105);box-sizing: border-box;">数据来源 | 康希诺科创板招股书、科创板2020年财报</span></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">目前，国内每天可接种超350万余剂疫苗（至4月22日七日平均）<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[15]</span>。中国生物和科兴的疫苗是其中的主力。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">全国新冠疫苗已累计接种超2.0亿剂次<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[12]</span>。<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">若按康希诺100万剂的接种量，仅占总接种量的约1/200。</span>对于康希诺来说，目前最紧要的事情就是提升产能。否则，面对疫苗大户中国生物和科兴，康希诺在国内会非常被动。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在国外，自2021年2月份以来，康希诺先后在墨西哥、巴基斯坦、匈牙利、智利等4个国家获得紧急使用授权。强生和阿斯利康疫苗的负面消息，会影响到它的海外合约吗？</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">放大灯向康希诺发去相关问题，截至发稿，未获回复。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;width: 12.5%;height: auto;box-sizing: border-box;"><img data-ratio="1" data-src="https://2-im.guokr.com/5KRwUCQuZhDey20x7woqyC7jweA8dr3pf7x-TZuVIIhkAAAAZAAAAFBO.png" data-type="png" data-w="100" style="vertical-align: middle;width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/5KRwUCQuZhDey20x7woqyC7jweA8dr3pf7x-TZuVIIhkAAAAZAAAAFBO.png" referrerpolicy="no-referrer"></section></section><section style="max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;justify-content: center;align-items: center;flex-direction: column;max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;box-sizing: border-box;"><section style="display: flex;padding-top: 3px;padding-bottom: 3px;flex-direction: column;justify-content: center;border-bottom: 2px dashed rgb(219, 175, 105);max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="text-align: unset;background-color: rgb(255, 206, 0);padding-left: 15px;padding-right: 15px;padding-top: 1px;max-width: 100%;font-size: 16px;color: rgb(17, 17, 17);box-sizing: border-box;"><p style="min-width: 1px;font-weight: bold;box-sizing: border-box;"><strong style="box-sizing: border-box;">舍近逐远，自造疫苗</strong></p></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">从去年至今，康希诺在加紧自建疫苗生产车间的同时，也开始寻找合作代工方。与国内的代工方上海医药的生产线，到2021年7月份可以投产。而这距离康希诺获批上市，已间隔5个月。</p><p style="white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;">另一家宣布进军腺病毒疫苗生产的企业，情况则更扑朔迷离。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">旗下只有一款治疗心力衰竭的产品、从未进行过疫苗开发的西藏药业，去年11月宣布引进俄罗斯的卫星-V疫苗。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">但半年时间过去了，西藏药业一支疫苗也拿不出。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">到了4月初，心急的投资者在交易所互动平台上提问：“快马加鞭，争分夺秒，时间紧任务重，及时完整准确的披露，用词用的非常厉害。我就想知道你们的奉贤厂房几月份建好，<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">卫星-V疫苗几月份能生产出第一瓶</span>？”</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">对此，西藏药业回复称，其在上海奉贤园区的生产线建设已经开始，预计在2021年9月前完成生产线建设并投入生产<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[16]</span>。从引进到试生产，西藏药业要花足足10个月。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">如今看来，国内的腺病毒厂商，至少面对着两个问题：</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">一是，随着接种量的进一步提升，还不能排除疫苗出现血栓副作用的可能。</span>仅仅是这种“可能”，对一款新冠疫苗撑起千亿市值的康希诺来说，已足够令资本市场和投资者焦虑。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">而阿斯利康新冠疫苗在血栓问题上的后续表现，则会直接影响该疫苗的中国引进者——康泰生物的命运。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">二是，国内腺病毒疫苗厂商的产能，出现了较为严重的<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">“错配”</span>问题。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在国内的腺病毒疫苗供应十分紧缺的情况下，整个行业却将要为国外代工1.6亿剂的疫苗。华兰生物是国内最大的流感疫苗公司，声名在外。源兴基因虽然名气不大，但它们都为俄罗斯代工卫星-V，足以证明这两家企业有制造腺病毒疫苗的能力（据相关报道，源兴<span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">基因</span>的生产5月即会启动<span style="color: rgb(219, 175, 105);box-sizing: border-box;">[17]</span>）。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">既然如此，西藏药业、康希诺为何都<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">死守自产疫苗的路线，</span>而不是灵活地利用现有产能，及早让疫苗大规模上市？</p><p style="white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;">康希诺尚且找了上海医药合作，但西藏药业明显并不心急。要再过5个月，它的产线才有可能建好。抑或是，“自建数亿产能”虽然极度艰难甚至并不现实。<span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">但藉此为投资者画出一张大饼，已绰绰有余。</span><span style="background-color: rgb(255, 206, 0);"></span></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.6296296" data-src="https://3-im.guokr.com/HNtDG6TGgv8LTUvlcjGgWLocWhK3r0-VICakPFmxR_E4BAAAqAIAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;" src="https://3-im.guokr.com/HNtDG6TGgv8LTUvlcjGgWLocWhK3r0-VICakPFmxR_E4BAAAqAIAAFBO.png?imageView2/1/w/555/h/349" referrerpolicy="no-referrer"></section></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><br></section></section><section style="margin-top: 10px;margin-bottom: 10px;text-align: center;justify-content: center;opacity: 0.9;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: inline-block;width: 90%;border-width: 1px;border-style: dashed;border-color: rgb(219, 175, 105);padding: 5px 10px;background-color: rgba(232, 224, 65, 0);border-radius: 0.7em;height: auto;box-sizing: border-box;"><section style="text-align: justify;color: rgb(219, 175, 105);box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;font-family: -apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size: 17px;letter-spacing: 0.544px;white-space: normal;background-color: rgb(255, 255, 255);opacity: 1;transform: rotateZ(0deg);box-sizing: border-box;overflow-wrap: break-word !important;"><section style="margin-top: 10px;margin-bottom: 10px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="margin: -15px 15px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="max-width: 100%;letter-spacing: 2px;box-sizing: border-box;overflow-wrap: break-word !important;"><p style="max-width: 100%;min-height: 1em;text-align: left;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="max-width: 100%;font-size: 12px;letter-spacing: 1px;box-sizing: border-box;overflow-wrap: break-word !important;">References</span><span style="font-size: 12px;letter-spacing: 1px;box-sizing: border-box;">：</span></p><section style="margin-top: 5px;margin-bottom: 5px;max-width: 100%;font-size: 12px;letter-spacing: normal;text-align: left;line-height: 1.75em;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="max-width: 100%;display: inline-block;width: 416px;height: 240px;vertical-align: top;overflow-y: auto;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="max-width: 100%;overflow-x: hidden;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="padding-right: 8px;padding-left: 8px;max-width: 100%;text-align: justify;box-sizing: border-box;overflow-wrap: break-word !important;"><p style="box-sizing: border-box;">[1] 世卫组织新冠疫苗紧急使用清单评估进度表</p><p style="box-sizing: border-box;">https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_16Feb2021.pdf</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[2] 丹麦宣布停用阿斯利康疫苗 发布会上一官员突然晕倒.中国新闻网.2021.4.15</p><p style="box-sizing: border-box;">http://www.chinanews.com/gj/2021/04-15/9455375.shtml</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[3] CDC and FDA recommend US pause use of Johnson & Johnson's Covid-19 vaccine over blood clot concerns</p><p style="box-sizing: border-box;">https://edition.cnn.com/2021/04/13/health/johnson-vaccine-pause-cdc-fda/index.html</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[4] 席华龙，顾韩雪：人腺病毒疫苗的研究进展.中国生物制品学杂志.2021 年 4 月第 34 卷第 4 期:P493~497</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[5] 毛振华：埃博拉疫苗撬动康希诺生物加快疫苗研发创新步伐.新华网.2019.07.23</p><p style="box-sizing: border-box;">http://m.xinhuanet.com/tj/2019-07/23/c_1124787914.htm</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[6] 钱童心：康希诺疫苗有望在加拿大生产，有望秋天可用.第一财经.2020.05.13</p><p style="box-sizing: border-box;">https://www.yicai.com/news/100627635.html</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[7] 强生官网：我们对于抗击埃博拉疫情的承诺</p><p style="box-sizing: border-box;">https://www.jnj.com/combating-ebola-fact-sheet</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[8] 陶立峰，蒲 江：结核病疫苗研究进展.中国新药杂志2019年第28卷第21 期:P2624~2629</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[9] 钱童心：药明生物收购拜耳德国一工厂 加速全球化扩张.第一财经.2021.03.28</p><p style="box-sizing: border-box;">https://www.yicai.com/news/101001802.htm</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[10] 世卫组织：全球疫苗安全咨询委员会(GACVS)审查阿斯利康COVID-19疫苗(Vaxzevria和Covishield)罕见不良凝血事件的最新证据</p><p style="box-sizing: border-box;">https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield)</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[11] 康希諾生物股份公司自愿公告</p><p style="box-sizing: border-box;">http://www.cninfo.com.cn/new/disclosure/detail?stockCode=06185&announcementId=1209687001&orgId=9900038913&announcementTime=2021-04-14</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[12] 4月20日国务院联防联控机制就新冠疫苗接种有关情况举行发布会（实录全文）</p><p style="box-sizing: border-box;">https://mp.weixin.qq.com/s/mYqbZOWILfbFf6-F9zo19g</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[13] 章遇：康希诺2020年亏损近4亿，研发投入暴增172%，新冠疫苗年内产能可达5亿-6亿剂.时代周报.2021.3.30</p><p style="box-sizing: border-box;">http://www.time-weekly.com/post/279783</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[14] 康希诺生物股份公司2020年财务报表及审计报告</p><p style="box-sizing: border-box;">http://static.cninfo.com.cn/finalpage/2021-03-29/1209468172.PDF</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[15] 国家卫健委疫苗接种情况数据页</p><p style="box-sizing: border-box;">http://www.nhc.gov.cn/xcs/yqjzqk/list_gzbd.shtml</p><p style="box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="box-sizing: border-box;">[16] 卫星5疫苗几月份能生产出第一瓶？西藏药业根据与俄罗斯签署的相关协议做出回应.每日经济新闻.2021.4.1</p><p style="box-sizing: border-box;">http://www.nbd.com.cn/articles/2021-04-01/1683208.html</p><p style="box-sizing: border-box;"><br></p><p style="box-sizing: border-box;">[17] 俄直投基金宣布5月起将与中国公司在华生产超六千万剂俄“卫星V”疫苗</p><p style="box-sizing: border-box;">http://sputniknews.cn/covid-2019/202103291033367192/</p></section></section></section></section></section></section></section></section></section></section></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.188781" data-src="https://3-im.guokr.com/jJRQVgk_rAonc5qm1V2ZjQ3_eA8FPtikqdvzC_gbjNefAwAArwAAAFBO.png" data-type="png" data-w="927" style="vertical-align: middle;box-sizing: border-box;" src="https://3-im.guokr.com/jJRQVgk_rAonc5qm1V2ZjQ3_eA8FPtikqdvzC_gbjNefAwAArwAAAFBO.png?imageView2/1/w/555/h/104" referrerpolicy="no-referrer"></section></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;border-width: 3px;border-radius: 15px;border-style: solid;border-color: rgb(37, 37, 37);overflow: hidden;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146139&idx=1&sn=73bc7bd1bcd7e60157c9453d6109644d&chksm=f01673bbc761faada305f897c115af9b72085f04cac43dd1b6a4591c8705ee5eee72a84ddac9&scene=21#wechat_redirect" textvalue="你已选中了添加链接的内容" data-itemshowtype="0" tab="innerlink" data-linktype="1"><span class="js_jump_icon h5_image_link" data-positionback="static" style="inset: auto;margin: 0px;"><img data-croporisrc="https://mmbiz.qpic.cn/mmbiz_jpg/nY1TzTHeMNlibalZ2RBTusHiccYPfJHNah3527iatDfOicaP3tUqmj82RUAPu7G9rj8nypH7wfBa7ShK1ZnbRyIyFg/0?wx_fmt=jpeg" data-cropx1="0" data-cropx2="1280" data-cropy1="2.302158273381295" data-cropy2="322.3021582733813" data-ratio="0.24921875" data-src="https://3-im.guokr.com/HcjRAJ_dOHJr0GUaVuYhxely-RPHNvZQNw96qvnQ0mQ4BAAADQEAAEpQ.jpg" data-type="jpeg" data-w="1280" style="vertical-align: middle;box-sizing: border-box;width: 556px;height: 139px;margin: 0px;" src="https://3-im.guokr.com/HcjRAJ_dOHJr0GUaVuYhxely-RPHNvZQNw96qvnQ0mQ4BAAADQEAAEpQ.jpg?imageView2/1/w/555/h/138" referrerpolicy="no-referrer"></span></a></section></section><section style="text-align: center;color: rgb(38, 38, 38);font-size: 14px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146139&idx=1&sn=73bc7bd1bcd7e60157c9453d6109644d&chksm=f01673bbc761faada305f897c115af9b72085f04cac43dd1b6a4591c8705ee5eee72a84ddac9&scene=21#wechat_redirect" textvalue="《苹果开春季发布会了，新款iPad mini、AirPods都没发布》" data-itemshowtype="0" tab="innerlink" data-linktype="2"><span style="box-sizing: border-box;">《</span>苹果春季发布会：新款iPad mini、AirPods、iOS 14.5……都没发布<span style="box-sizing: border-box;">》</span></a><span style="box-sizing: border-box;"></span></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;border-width: 3px;border-radius: 15px;border-style: solid;border-color: rgb(37, 37, 37);overflow: hidden;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146107&idx=1&sn=4cdbd17435206782f105b2d3db4e0ddd&chksm=f01673dbc761facdc1a247dab470b2d3be361016ee7054214e273a8469d60aef0bd57be49edb&scene=21#wechat_redirect" textvalue="你已选中了添加链接的内容" data-itemshowtype="0" tab="innerlink" data-linktype="1"><span class="js_jump_icon h5_image_link" data-positionback="static" style="inset: auto;margin: 0px;"><img data-croporisrc="https://mmbiz.qpic.cn/mmbiz_png/nY1TzTHeMNkmEickBHBSfxcGr7FFPhhhCq08plcKSpjXosISydGOs7LtvSssHqibfNIy836ps4ctJInmAhuds1mA/0?wx_fmt=png" data-cropx1="0" data-cropx2="900" data-cropy1="59.89208633093525" data-cropy2="284.89208633093523" data-ratio="0.25" data-src="https://1-im.guokr.com/ZbjxD5LK3j6Ko0XYMvvSez8eMEsoXeT7K9aXLMac_U6EAwAA4QAAAEpQ.jpg" data-type="jpeg" data-w="900" style="vertical-align: middle;box-sizing: border-box;width: 556px;height: 139px;margin: 0px;" src="https://1-im.guokr.com/ZbjxD5LK3j6Ko0XYMvvSez8eMEsoXeT7K9aXLMac_U6EAwAA4QAAAEpQ.jpg?imageView2/1/w/555/h/138" referrerpolicy="no-referrer"></span></a></section></section><section style="text-align: center;color: rgb(38, 38, 38);font-size: 14px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146107&idx=1&sn=4cdbd17435206782f105b2d3db4e0ddd&chksm=f01673dbc761facdc1a247dab470b2d3be361016ee7054214e273a8469d60aef0bd57be49edb&scene=21#wechat_redirect" textvalue="《10年过去，人们买不起旗舰机了》" data-itemshowtype="0" tab="innerlink" data-linktype="2"><span style="box-sizing: border-box;">《</span>10年过去，人们买不起旗舰机了<span style="box-sizing: border-box;">》</span></a><span style="box-sizing: border-box;"></span></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;border-width: 3px;border-radius: 15px;border-style: solid;border-color: rgb(37, 37, 37);overflow: hidden;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146091&idx=1&sn=288c356aab54bd873d418067823e6fbe&chksm=f01673cbc761faddf72cf7e475922c4affe866095377adbc43d3b218d6ab49ddece1963c459b&scene=21#wechat_redirect" textvalue="你已选中了添加链接的内容" data-itemshowtype="0" tab="innerlink" data-linktype="1"><span class="js_jump_icon h5_image_link" data-positionback="static" style="inset: auto;margin: 0px;"><img data-croporisrc="https://mmbiz.qpic.cn/mmbiz_jpg/nY1TzTHeMNnGaOerJDTsXfUldBahDkLmUbf4KI3H71gRFQstV5QPsqlmTqAibRmlDVSoPy8038EPaXaSd8C4hVg/0?wx_fmt=jpeg" data-cropx1="0" data-cropx2="900" data-cropy1="87.41007194244604" data-cropy2="312.41007194244605" data-ratio="0.24888888888888888" data-src="https://1-im.guokr.com/3rBjKCE_NQfwLFaFXI9vZVBDFHsTMLc5DRB8yyTOCIGEAwAA4AAAAEpQ.jpg" data-type="jpeg" data-w="900" style="vertical-align: middle;box-sizing: border-box;width: 556px;height: 139px;margin: 0px;" src="https://1-im.guokr.com/3rBjKCE_NQfwLFaFXI9vZVBDFHsTMLc5DRB8yyTOCIGEAwAA4AAAAEpQ.jpg?imageView2/1/w/555/h/138" referrerpolicy="no-referrer"></span></a></section></section><section style="text-align: center;color: rgb(38, 38, 38);font-size: 14px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146091&idx=1&sn=288c356aab54bd873d418067823e6fbe&chksm=f01673cbc761faddf72cf7e475922c4affe866095377adbc43d3b218d6ab49ddece1963c459b&scene=21#wechat_redirect" textvalue="《光伏制氢，双倍清洁，双倍快乐？》" data-itemshowtype="0" tab="innerlink" data-linktype="2"><span style="box-sizing: border-box;">《</span>光伏制氢，双倍清洁，双倍快乐？<span style="box-sizing: border-box;">》</span></a><span style="box-sizing: border-box;"></span></p><p style="box-sizing: border-box;"><span style="box-sizing: border-box;"><br></span></p><p style="box-sizing: border-box;"><img data-ratio="0.9185185" data-src="https://3-im.guokr.com/dBb5ANIh1Yt8KIxe0A7OYs011c-FLdD9o-PVL7b8ZsQ4BAAA4AMAAFBO.png" data-type="png" data-w="1080" style="color: rgb(62, 62, 62);font-size: 15px;vertical-align: middle;box-sizing: border-box;" src="https://3-im.guokr.com/dBb5ANIh1Yt8KIxe0A7OYs011c-FLdD9o-PVL7b8ZsQ4BAAA4AMAAFBO.png?imageView2/1/w/555/h/509" referrerpolicy="no-referrer"></p></section></section>
                  
</div>
            